Belgium pharmaceutical group Argenx has won a licence to develop and commercialise an experimental drug jointly created with AbbVie group Argenx in a deal that could generate payments of up to $625m . The cancer immunology drug ARGX-115 is one of many autoimmune and cancer drugs being tested by Belgium and US -based Argenx . ARGX-115 is in pre-clinical development, meaning it still has several stages of clinical trials to pass before it could enter the market. ARGX-115 has been jointly developed by both firms but has to go through several more clinical trials before being commercially launched. Argenx ’s share price rose 6% on the licensing news.
Belgium pharmaceutical group Argenx has won a licence to develop and commercialise an experimental drug jointly created with AbbVie group Argenx in a deal that could generate payments of up to $625m . The cancer immunology drug ARGX-115 is one of many autoimmune and cancer drugs being tested by Belgium and US -based Argenx . ARGX-115 has been jointly developed by both firms but has to go through several more clinical trials before being commercially launched. Argenx ’s share price rose 6% on the licensing news.